Firebrick Pharma Ltd

AU:FRE Australia Drug Manufacturers - General
Market Cap
$8.60 Million
AU$13.89 Million AUD
Market Cap Rank
#32137 Global
#1034 in Australia
Share Price
AU$0.06
Change (1 day)
+0.00%
52-Week Range
AU$0.05 - AU$0.09
All Time High
AU$0.65
About

Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.

Firebrick Pharma Ltd - Asset Resilience Ratio

Latest as of December 2024: 0.29%

Firebrick Pharma Ltd (FRE) has an Asset Resilience Ratio of 0.29% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
AU$5.35K
Cash + Short-term Investments
Total Assets
AU$1.84 Million
All company assets
Resilience Assessment
Low
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2021)

This chart shows how Firebrick Pharma Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Firebrick Pharma Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$5.35K 0.29%
Total Liquid Assets AU$5.35K 0.29%

Asset Resilience Insights

  • Limited Liquidity: Firebrick Pharma Ltd maintains only 0.29% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Firebrick Pharma Ltd Industry Peers by Asset Resilience Ratio

Compare Firebrick Pharma Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Novartis AG
PINK:NVSEF
Drug Manufacturers - General 0.13%
Pfizer Inc
NYSE:PFE
Drug Manufacturers - General 7.18%
AbbVie Inc
NYSE:ABBV
Drug Manufacturers - General 0.02%
Biogen Inc
NASDAQ:BIIB
Drug Manufacturers - General 2.74%
Zhejiang Int'L Group Co Ltd
SHE:000411
Drug Manufacturers - General 0.00%
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
Drug Manufacturers - General 5.75%
Hunan Jingfeng Pharmaceutical
SHE:000908
Drug Manufacturers - General 0.38%
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
Drug Manufacturers - General 5.37%

Annual Asset Resilience Ratio for Firebrick Pharma Ltd (2021–2021)

The table below shows the annual Asset Resilience Ratio data for Firebrick Pharma Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2021-06-30 2.41% AU$283.24K AU$11.77 Million --
pp = percentage points